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Helicobacter pylori is a common microaerophilic gram-negative bacterium that 
infects approximately 50% of the human population. Although all H. pylori infections 
result in inflammation of the gastric epithelium, only 10-15% of infections are 
symptomatic and progress to severe gastric diseases such as gastric and duodenal ulcers, 
MALT lymphoma and gastric cancer. Different disease outcomes are due in part to 
genetic variations among H. pylori strains. Helicobacter pylori strains with a genomic 
region called the cytotoxin-associated pathogenicity island (cagPAI) are associated with 
an increased risk of severe disease. The cagPAI region encodes a type IV secretion 
system that transports the CagA effector into host gastric epithelial cells. Regulation of 
the cagPAI is a vital area of research. Previous studies on H. pylori and other bacteria 
have found that small RNAs (sRNAs) play a role in gene regulation. These transcripts are 
50-300 nucleotides in length and act independently on expressed targets. sRNAs serve to 
regulate and fine-tune gene expression by interacting with target mRNA molecules to 
inhibit or accelerate gene translation or function. Understanding how cagPAI genes are 
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regulated is key to understanding how they promote disease. Herein, I investigate three 
cagPAI located sRNAs HPnc2525, HPnc2600, and HPnc2645 identified in previous 
studies. Using bioinformatics, conservation, and visual inspection, I predicted promoters 
and terminators for HPnc2525, HPnc2600, and HPnc2545. I devised an RT-PCR primer 
walking strategy to delimit the 5' end of HPnc2525 further. I analyzed the sRNA 
sequences defined by this and previous research using the TargetRNA2 program and 
predicted these sRNAs regulate virulence (e.g., cagL, hopZ, and fliA) and other genes. 
Due to CoVID-19, I was unable to verify sRNA interactions with their predicted targets 
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Due to the global pandemic of COVID-19, time in the lab was cut short. Instead, 
the research took on more a bioinformatic approach to elucidate other aspects of my 
research. Much of the preliminary planning and preparation for the physical experiments 
were completed, and this will offer researchers taking on the next step a fantastic place to 





















Introduction to Helicobacter pylori 
Helicobacter pylori is a rod-shaped microaerophilic gram-negative 
Epsilonproteobacteria. It is approximately 2.4-4.0 µm by 0.5-1.0 µm and has two to six 
flagella that facilitate movement to penetrate gastric mucosa and counteract gastric efflux 
mechanisms1. Helicobacter pylori is a human-adapted gastric Helicobacter species 
located in the human gastric mucosa of approximately 50 percent of the human 
population, making it one of the most common infections in the world1,2. Other 
Helicobacter species are zoonotic and rarely can be found on Humans3. 
Coevolution between H. pylori and humans share a 58,000-year history with 
predominant strains located regionally along with human migration patterns4. The global 
distribution of H. pylori genetic diversity is a mirror of its human host, and simulations 
have also predicted the spread of H. pylori from east Africa to around the world over the 
same time scale of humans4. It has been shown that human populations located in areas 
with notably higher documented intestinal parasite load were found to have an immune 
response against H. pylori toward a T helper type 2 (Th2) (anti-inflammatory), thereby 
preventing T helper type 1 (Th1) responses associated with mediated microbicidal action, 
gastric inflammation, and corpus atrophy5,6. This interaction may, in turn, affect the 
selection of H. pylori strains in the host, favoring the loss of cagPAI, which is known to 
be associated with Th1 type responses5. 
Although the H. pylori infection rate is high worldwide, its prevalence varies 
dramatically in different regions; prevalence is higher in developing than developed 
countries, and in developed countries, infection is inversely correlated with access to 
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good sanitation1,2. Regions of Africa and South America were found to have the highest 
rates of infection at 70.1% and 69.4% respectively, and Nigeria was found to have the 
highest prevalence with 87.7% of the population infected2. In more developed regions 
such as North America, the population infection rate is 37.1%2. However, in these 
developed countries, it has been found that certain genetic groups have a disproportionate 
infection rate compared to the region's average infection rate2. In the United States, 
prevalence among non-Hispanic whites ranges from 18.4% to 26.2%. Non-whites 
conversely range from 34.5% to 61.6% (Fig. 1)7.  
 
Figure 1. Helicobacter pylori Prevalence Worldwide. (Hooi, J. et al., 2017) 
Helicobacter pylori is mainly spread within close family groups who have 
diminished access to clean water and are of lower socioeconomic status. However, 
infection rates are lower in children and adolescents, although infection tends to occur at 
a younger age and is lifelong without antibiotic treatment2,8. The main modes of 
transmission are through oral/oral, gastro/oral, and fecal/oral routes1,9. Oral-oral and 
gastro-oral transmission occur via direct contact with an infected individual, such as 
kissing or sharing unwashed drinking containers10. Helicobacter pylori infection 
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prevalence has also been found to be significantly higher among intimate partners via an 
oral/oral route10. One is four times as likely to be infected if their partner has H. pylori-
related gastroesophageal reflux. However, the infection can still be spread from 
asymptomatic partners but to a lesser extent10. Fecal-oral transmission takes a more 
indirect route. Infected individuals can pass H. pylori through fecally contaminated water. 
In areas with lower water sanitation standards, H. pylori can be transmitted to a new host 
either by drinking contaminated water directly or eating food that has been contaminated 
with the unclean water9,11.  
Helicobacter pylori Caused Gastric Disease 
Although H. pylori infections are common, only 10-15% results in disease12. All 
H. pylori infections result in some level of chronic active gastritis, but most do not result 
in apparent symptoms or other complications13. Symptomatic infections include gastric 
cancer, acute and chronic gastritis, gastric and duodenal ulcers, functional dyspepsia, and 
mucosa-associated lymphoid tissue (MALT) lymphoma. 
Successful colonization of the host gastric mucosa by H. pylori always results in 
acute and chronic gastritis, but these are not always symptomatic13. Acute gastritis is 
associated with nonspecific dyspeptic symptoms and also with hyperchlorhydria, the 
increased production of acid14. The main dyspeptic symptoms associated with H. pylori 
infection are reflux-like with heartburn and regurgitation. Chronic gastritis, because of 
permanent colonization, affects acid production and, when coupled with cellular 
disruption, can promote different diseases. A combination of H. pylori virulence factors, 
host factors, and host environmental factors plays a part in the acid production of the 
stomach and, in turn, where it colonizes14. An environment of low acidity leads to more 
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broad colonization of the stomach, in the antrum (lower), corpus (middle), and fundus 
(upper), which is associated with gastric carcinoma15. Conversely, an environment with 
higher acid production leads to more limited stomach colonization, mainly in the gastric 
antrum, which has a lower number of acid-secretory cells. This antral-predominant 
gastritis from H. pylori colonization is the leading cause of peptic ulcer disease (PUD) 
(Fig. 2)14. 
 
Figure 2. Locations of Helicobacter pylori Colonization 
With a combination of host and environmental factors, H. pylori can colonize distinct 
locations in the stomach leading to different disease states. Pink areas represent increased 




Helicobacter pylori was discovered in 1983 to be a cause of PUD and is still 
regarded as the primary pathogen associated with it2,3,16. PUD is caused by defects in the 
gastric mucosa that occur along with the transition from the corpus to antrum17. 
Helicobacter pylori presence has been found in about 82% of duodenal ulcers and 68% of 
gastric ulcers18. The risk of PUD is 3 to 10 times greater in people with H. pylori 
infection than without19. Eradication of the infection by antibiotic treatment or triple 
therapy (oral proton pump inhibitor, clarithromycin, and amoxicillin) has been found to 
reduce the risk of this disease20. 
Chronic infection with H. pylori is linked to gastric adenocarcinoma and MALT 
lymphoma, which accounts for 25% of cancers associated with infectious agents21. 
MALT lymphoma was first associated with H. pylori in 1991 and is now known to be 
responsible for 92-98% of all gastric MALT lymphoma21. This type of lymphoma is a 
non-Hodgkin B-cell neoplasm, which originates from the marginal zone of lymphoid 
follicles22. Although not contributing to increased risk, the presence of the H. pylori 
virulence protein cytotoxin-associated gene A (CagA) in tumor-associated B cells 
correlated with earlier pathogenic remission times, possibly due to the translocation of 
CagA into malignant B cells23. Eradication of H. pylori leads to remission in 80% of 
MALT lymphoma patients, but other cancers have been linked to H. pylori infection, 
such as Pseudomyxoma peritonei (PMP), laryngeal/pharyngeal cancer, and other 
lymphomas12,24. Pre-surgery H. pylori eradication with these other cancers has shown an 
increased length of patient survival over non-treated patients12,24.  Helicobacter pylori is 




Functional Dyspepsia, or non-ulcer Dyspepsia, is one of the most common 
sensorimotor disorders involving the gastrointestinal tract26. It is defined as the presence 
of one or more of the following symptoms: bothersome postprandial fullness (full 
stomach feeling), bothersome early satiation (inability to eat), bothersome epigastric pain 
(upper abdomen), or bothersome epigastric burning (heartburn), and no evidence of 
structural disease (including upper endoscopic findings) to explain the symptoms27. The 
main symptoms of H. pylori are reflux-like with heartburn and regurgitation. It may be 
similar to ulcer-related dyspepsia, causing pain and vomiting. Of patients that exhibit the 
symptoms associated with Functional Dyspepsia, it is estimated that 30-60% carry H. 
pylori28. 
 Our initial understanding of the role of H. pylori-induced carcinoma was believed 
to be the result of a long-term inflammation process. Whereby a Th1 type immune 
response led to the apoptosis of gastric epithelial cells and thus increased cell growth to 
compensate29,30. This damage led to errors during mitosis and accumulated mutations in 
the host cells, which is further compounded by a deficiency of the DNA mismatch repair 
mechanism in the host cells induced by H. pylori infection31. Recent studies have 
suggested that the CagA protein may also have a carcinogenic effect via interactions with 
proteins of the tight junctions and adherent junctions, leading to a breakdown of these 
junctions and uncontrolled activation of β-catenin, which will lead to tumor 
production3,32,33. Conclusive evidence for this interaction and carcinogen nature was 
shown in transgenic mouse experiments34.  
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Helicobacter pylori Caused Extragastric Disease 
Extragastric diseases with which H. pylori infection may also be associated 
include iron deficiency anemia, idiopathic thrombocytopenic purpura (ITP), skin 
diseases, pregnancy diseases, liver and gallbladder, pulmonary, ocular, 
neurodegenerative, cardiovascular, autoimmune, neuromyelitis optica, multiple sclerosis, 
insulin resistance, diabetes, and ear nose and throat12. Helicobacter pylori's presence in 
these different areas of the body shows that it is not just isolated to the stomach, as was 
initially thought. Other than the stomach, H. pylori has been cultured and observed 
histologically in the nasal cavity, coronary arteries, liver, and peritoneum12. The 
relationships and their significance of H. pylori in these extragastric locations are debated 
and are still being investigated. 
Factors Affecting Disease Outcome 
Human factors affecting disease outcomes include age, alcohol intake, nicotine 
intake, and salt intake7. These factors all affect H. pylori antibody serum levels but in 
separate ways. For example, age, salt, and nicotine intake are associated with a marked 
increase in serum antibody presence35-37. Nicotine causes vasoconstriction body-wide, 
thus reducing mucosal blood flow, epidermal growth factor secretion, and mucus 
secretion36. High salt concentration in the stomach was found to alter the H. pylori 
exoproteome, increasing the secretion of the H. pylori virulence factor VacA35. Alcohol, 
however, has an inverse effect on antibody serum levels, which is believed to be the 
result of lower pH in the stomach due to increased stimulation of gastric acid secretion38. 
Human genetic diversity can also lead to differing immune responses, which in 
turn can affect disease states. Increased gastric cancer risk can stem from functional 
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polymorphisms in the genes encoding interleukins (ILs). ILs are a group of cytokines, 
proteins, and other signaling molecules, which are an essential part of the immune 
system. In particular, functional polymorphism in IL-1β (responsible for antimicrobial 
resistance and inflammation) and IL-1 receptor antagonists (the natural inhibitor of the 
proinflammatory effects of IL-1β), as well as differing the amount of IL-1β secreted from 
the microbial response, have shown to increase gastric cancer risk39. An increase in 
colony density in patients lacking blood group antigen Leb has been noted as well40. 
These individuals are lacking Leb due to the fact they genetically have no Le gene or they 
have an Le gene but no Se gene41. Other polymorphisms exist in genes, increasing 
proinflammatory cytokines or reducing anti-inflammatory cytokines. Helicobacter pylori 
primarily mediates a Th1 response42. This response is associated with proinflammatory 
cytokine release, such as the cytokine important for innate and adaptive immunity against 
viral, some bacterial and protozoal infections, interferon-gamma (IFN-γ), as well as the 
activation of macrophages. This strong Th1 response leads to worse outcomes due to 
chronic inflammation and gastric atrophy. However, a Th2 response can mediate this 
effect43. There is a noted Th1 bias in patients from Japan and the United Kingdom who 
also present a higher level of disease44. 
Conversely, human populations in Africa present a lower instance of disease 
levels with a marked increase of Th2 response instead of Th144. The mechanism for 
controlling Th response in humans is comprised of regulatory T-cells (Tregs), which are a 
specific population of T-cells that can maintain homeostasis and self-tolerance by 
suppression of the immune response45. The gastric mucosa of H. pylori-positive 
individuals contains high levels of immunosuppressive cytokines IL-10 (anti-
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inflammatory) and transforming growth factor beta 1 (TGF- β1), which controls 
proliferation and differentiation of many cell types46. Tregs also suppress IL-8 (induces 
chemotaxis and stimulates phagocytosis) production from gastric epithelial and memory 
cell responses in the presence of H. pylori46. Helicobacter pylori can induce a Treg 
response, which may be a reason for its relatively benign coexistence with the human 
host. However, patients with PUD have decreased Tregs in their gastric mucosa, which 
highlights the importance of a balanced regulatory response47. Coevolution between H. 
pylori and humans spans 58,000-years, and while the human genetic diversity plays a role 
in disease, so does the genetic diversity of H. pylori itself4. 
Bacteria Genetic Diversity Promoting Disease 
There are four steps crucial for H. pylori colony establishment and pathogenicity, 
and the presence of genes required for these steps varies among H. pylori strains. When 
entering the host stomach, H. pylori must be able to survive in the acidic stomach. 
Survival is facilitated by the production of urease, which hydrolyzes host produced urea 
to ammonia and carbonic acid, serving as a buffer to the microenvironment enabling 



















Figure 3. Helicobacter pylori can Neutralize Stomach pH 
To successfully colonize the gastric mucosa, H. pylori neutralizes urea with urease. The 
pink area represents a high acid environment (≤ pH 2), and the blue area represents a 
lower acidity environment (≥pH4) due to the effects of urease. Urea from the 
environment enters through proton-gated channels (orange) on the surface of the 
bacterium. Urease breaks down the urea creating CO2 (orange square) and NH3 (blue 
triangles). The latter is excreted through proton-gate channels on the surface of the 
bacterium, raising the pH in the vicinity. 
 
The urease gene cluster contains seven genes, including catalytic subunits (ureA/B), an 
acid-gated urea channel (ureI), and accessory assembly proteins (ureE-H)48. To prevent 
lethal alkalization, this activity is regulated by the proton-gated urea channel UreI. This 
regulation functions by only being active under acidic conditions, such that UreI channels 
in the inner membrane are closed at pH 7.0 and fully open at pH 5.049. The surface of H. 
pylori also contains urease, which allows the bacteria to pass through the gastric 
environment unscathed49. Furthermore, urease has been found to regulate macrophage 
interactions by modulating phagosome pH and megasome formation and reduce the 
viscosity of gastric mucin50,51. 
While traversing the gastric mucosa, the next crucial step in colony establishment 
is the ability to move further toward epithelium cells. Helicobacter pylori, motility is 
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directly correlated with a rise in pH. Helicobacter pylori achieves motility by reducing 
the viscosity of its environment; it does not bore its way through the mucus gel, as 
previously thought50. It can then move through the gastric mucosa epithelium layer 
toward the basal layer when the pH is more neutral, and the bacteria have disrupted the 
tight cell junctions. Both its helical shape and flagella help it move into its 
microenvironment. Helicobacter pylori rotates as it swims, producing a helical trajectory, 
but the relatively slow body rotation rates make only a 15% contribution to propulsive 
thrust52. Thus, the flagella have more of an impact on motility than its helical shape. This 
flagella-mediated motility is one of the most complex systems in H. pylori, with more 
than 40 proteins involved in biosynthesis and operation53. More severe pathological 
outcomes have been observed in patients infected with H. pylori strains with higher 
motility54. There is still debate about whether flagella directly participate in cell adhesion. 
However, it was found that regulators controlling flagella genes may affect adhesin 
expression as well55. 
Neutrophil-activating protein A (napA), a gene encoding H. pylori-NAP (HP-
NAP), is highly associated with chronic gastritis, as well as infiltration of neutrophils and 
mononuclear cells into the gastric mucosa56. HP-NAP is a member of the DNA-binding 
proteins from starved cells (Dps) family, which is highly similar to other bacterioferritin 
that store iron and bind and protect DNA57. However, HP-NAP differs as it induces large 
quantities of IL-12 and IL-8 via stimulation of both neutrophils and monocytes58,59. This 
stimulation, in turn, induces T-cells to secrete INF-γ and mediates the shift to a Th1 
response58. This adhesion to neutrophils causes damage to local tissue by stimulating a 
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high production of oxygen radicals60. HP-NAP also facilitates another adhesin, SabA, by 
mediating the binding of sialylated antigens on the host cell surface61. 
Both variably expressed blood group antigen-binding adhesin (BabA) and sialic 
acid-binding adhesin (SabA) facilitate colonization of the epithelial layer of the antrum of 
the stomach3,12. BabA binds to fucosylated Lewis B blood-group antigen that is expressed 
on the gastric epithelium cells62. Interestingly, strains that are deficient in BabA resulting 
from mutation still express a chimeric BabB/A, which can bind to the Leb antigen by 
genetic recombination in certain conditions63,64. SabA, on the other hand, recognizes the 
sialyl-Lewis A antigens sLex and sLea 65,66. Thus, the interaction of SabA and sLex 
antigen enhances H. pylori colonization in patients with weak or no Leb expression. 
After the pH has been addressed by urease and adhesion of H. pylori to epithelial 
cells occurs, the bacterium secretes or injects additional virulence factors into the 
cytoplasm to impact host cell physiology such as muramyl dipeptide (MDP) and 
Vacuolating toxin A (VacA) into their cytoplasm67. MDP, which is part of the 
peptidoglycan cell wall, is detected by the intracellular NOD receptors. These, in turn, 
activate the Nuclear factor-κB (NF-κB) pathway with the production of IL-8 and attract 
inflammatory cells67. Ultimately this immune response was found to be one-way 
epithelial cells that can differentiate pathogenic and non-pathogenic bacteria67,68. The 
presence ImaA, immunomodulatory autotransporter protein, can decrease this 
inflammation responses aiding in overall pathogenesis of H. pylori69. Also, VacA may 




Figure 4. Virulence Factor Vacuolating Toxin A (VacA) 
VacA enables H. pylori to remove nutrients from host cells when bound to the epithelium 
by an autotransporter system. VacA also promotes proinflammatory signaling, 
vacuolation (membranous spaces in the host cell cytoplasm), apoptosis, and after tight 
cell junction disruption, disruption of T-cell activation and proliferation. 
 
There are multiple alleles of vacA with different activities and different levels of 
expression that impact disease outcome70. VacA forms an autotransporter structure to 
secrete itself from H. pylori without the need for host cell contact12. VacA has been 
shown to disrupt the barrier function of epithelial cells, allowing leakage of essential 
nutrients needed by H. pylori for growth71. VacA embeds into the host cell membrane 
and functions as an anion-selection channel releasing bicarbonate and organic anions in 
the host cytoplasm72. In addition to embedding, VacA can also be endocytosed and allow 
15 
 
anions to enter late endosomes, creating large vacuoles71,73. Acute inflammatory 
responses can also be achieved by inducing the host cell to release IL-874. VacA also can 
cause mitochondrial dysfunction resulting in apoptotic death of the cell and T-cell 
blocking71. The presence of VacA can have a dramatic effect on epithelial cells; however, 
it is not clear whether VacA primarily causes a disease. Thus, it is believed that the 
ability of H. pylori to colonize a host successfully is merely enhanced via VacA75. 
The most significant and well researched H. pylori virulence factor is CagA. It 
will not function in isolation and works in concert with other virulence genes, those in the 
cagPAI genomic region12. This island is present in about half of the H. pylori strains, and 
its presence correlates with more severe disease states3,67,76. The cagPAI genes encode a 
type IV secretion system that enables the injection of CagA into host cells71. Once in the 
host cell cytoplasm, CagA is phosphorylated, which inhibits Src dephosphorylation, 
regulation of cellular matrix, and other cytoskeleton regulators in epithelial cells68,77. 
These will phenotypically change the cell and cause high markers of gastric cancer stem 






Figure 5. The Type IV Secretion System Injects CagA into the Epithelial Cell 
CagA disrupts the tight cell junction and disrupts the cellular matrix resulting in a 
hummingbird morphology. NOD1 also gets activated by iE-DAP, which in turn activates 
NF-κB, which subsequently produces proinflammatory signaling. 
 
Africa has been shown to have the highest prevalence of infection, even though the 
reported cases of gastric cancer were lower than regions with lower infection 
prevalence2,79. The most prevalent strain of H. pylori in South Africa, shpAfrica2, was 
found to lack the cagA gene2. Further studies have shown that increased pathogenicity 
correlated with the more virulent strains to create morphological changes, vacuole 
formation, and progressive epithelial cell degeneration13. There is a noted positive 
correlation with the severity of disease, and cagA-positive H. pylori strains in both 
humans and animals13,80. 
Not all virulence factors are present in each strain of H. pylori. Although, all 
known H. pylori strains contain vacA genes, not all the strains produce a functional VacA 
protein due to genetic polymorphisms81. BabA is almost always present in CagA positive 
strains, and the presence of cagA usually correlates with the presence of vacA, and 
proinflammatory outer membrane protein (oipA)12,56,82. The pathogenicity of H. pylori is 
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a result of several genes that are responsible for the production of these virulence factors, 






















Small Regulatory RNAs 
Regulatory RNAs (riboregulation) have been linked to bacteria pathogenicity83. 
Helicobacter pylori was previously believed to lack riboregulation, but recent studies 
revealing sRNA activity in H. pylori have challenged previous conclusions84,85. RNA 
regulators in bacteria are transcripts that use various mechanisms to change expression 
and promote a range of physiological responses86. These regulators come in different 
classes, such as riboswitches, small transcript binding proteins, CRISPR RNAs, and 
sRNAs86. The sRNA molecules are post-transcriptional regulators found in all kingdoms 
of life. They are short transcripts roughly 50-300 nucleotides in length and act on 
expressed mRNA targets through complementary base-pairing87. These interactions serve 
to regulate and fine-tune gene expression by inhibiting or accelerating mRNA translation 
through impacting access to the ribosome binding site and by impacting mRNA 
stability86. Of the various sets of sRNA, the most extensively studied are regulators that 
act through base pairing with mRNAs to affect their translation86. Cis-encoded antisense 
sRNAs are located in or near the same gene locus as their mRNA target and share 
complete base-pairing with their target, usually within the untranslated 5' region (Fig. 
6a)88. Alternatively, trans-encoded sRNA, whose target is genetically distant loci, has 
only partial and interrupted base pairing with its target (Fig. 6b)88. The last known 
interaction is Cis-encoded antisense acting in trans, which involves two sRNA 




Figure 6. sRNA Can Post-transcriptionally Regulate Genes in Diverse Ways 
(A) Cis-encoded antisense sRNA with complete base pairing with mRNA can form a 
complex of the coding region that gets degraded. (B) Genetically distant trans-encoded 
sRNA has only partial and interrupted base pairing that can enable upregulation by 
binding with the mRNA and opens access to the ribosome binding site. (C) Cis-encoded 
antisense acting in trans sRNAs involves two interactions, one in cis and one in trans. 
The sRNA can downregulate expression by binding to the ribosome binding site, thus 
blocking translation 
The majority of known sRNAs act by the cis-encoded antisense acting in trans 
mechanism whereby the cis-encoded sRNA acts both on the mRNA target it overlaps and 
mRNA targets at genetically distant loci86,88. The sRNAs can globally affect traits 
resulting from stress responses, adaptive metabolic changes, virulence, stalled ribosomes, 
uncharged tRNAs, elevated temperatures, or small molecule ligands at the post-
transcriptional level89. Hence, sRNAs have evolved as an additional form of gene 
regulation90. 
In some instances, proteins aid the sRNA to facilitate regulation. Helper proteins 
like Hfq often play critical roles in sRNA function. However, Epsilonproteobacteria, 
including H. pylori, have no apparent Hfq homolog91,92. Hfq is an RNA-binding protein 
that forms homohexamers of ~12 kDa subunits, which protects the sRNA to prevent 
degradation and allow the sRNA to bind to its mRNA target92. Although all forms of life 
contain sRNA, not all of them are the same, and it is not currently known how sRNAs 
work in H. pylori given the apparent lack of helper proteins. 
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Different methods, such as computer-aided target prediction and functional 
assays, have been developed to find the sRNAs targets. A biocomputational method 
(TargetRNA) was developed to predict targets of sRNAs using a calculated hybridization 
score for a given sRNA and a candidate mRNA candidate93. This tool was later refined to 
update efficiency and accuracy and is freely accessible on the web as TargetRNA293,94. 
Reporter assays have been developed to analyze sRNA-directed gene control that can be 
used for co-expression of an sRNA and a 5' sequence of an mRNA target fused to a green 
fluorescent protein (GFP) reporter95. Using this method, expression of the mRNA 
directed by the sRNA can be visualized by cloning GFP plasmids96. A super folder 
variant GFP (sfGFP) was later created, which results in increased fluorescence of target 
fusions, which is beneficial when the proteins do not fold flawlessly but still affect 
expression97. 
Role of Helicobacter pylori sRNA 
The H. pylori genome encodes relatively few transcriptional regulators, so how 
does it regulate all of its gene expression to respond to changing environmental 
conditions98. A potential answer came with the publication of four studies that together 
identified in excess of 60 H. pylori sRNAs. Livney et al. (2006) used sRNAPredict2 to 
identify sRNAs in intergenic regions with regards to the conservation of transcriptional 
regulatory elements, Rho-independent terminators, promoters, and with a size constraint 
of 60-550 nt in length99. They identified a total of 130 among six different strains of H. 
pylori; 50 were unique, 49 were conserved in at least two strains, and 29 were at least 
conserved in 3 strains99. Xiao et al. (2009) predicted six sRNAs based on gene location, 
promoter search, and terminator search100,101. Intergenic regions were screened in H. 
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pylori strain 26695 using pftools 2.2 to identify promoters, RNAmotif to identify hairpins 
followed by UU nucleotide sequences, and finally, if a promoter and terminator pair on 
one strand between 45 and 350nt between them100,101. These potential sRNAs were 
analyzed for conservation, which identified six sRNAs, and two were experimentally 
confirmed by Northern blot and RT-PCR100,101. Even though many sRNAs have been 
identified, only four have been well characterized. For example, a novel cis-encoded 
antisense small RNA was identified, which downregulated expression of the urease 
component, UreB, at neutral pH85. It was found that 5'ureB-sRNA, targets the 5' end of 
ureB and promotes premature termination of transcription of ureAB mRNA85. With this 
mechanism, a limited amount of 5'ureB-sRNA is sufficient to regulate the relatively high 
level of ureAB transcript102. This process effectively prevents urease from being produced 
when the environment does not demand it (Fig. 8a). 
The second characterized sRNA,  a trans-encoded sRNA repG, was shown to 
target a homopolymeric G-repeat in the mRNA leader of an acid-sensing chemotaxis 
receptor, TlpB84. This regulation of tlpB, which decreases expression could be necessary 
for H. pylori colonization, and research is still ongoing (Fig. 8b)84. Another H. pylori 
sRNA, CncR1, which is located in the cagPAI, has also been characterized76. CncR1 was 
found to target flagellar functions, specifically the flagellar checkpoint gene fliK. This 




Figure 7. Different regulation of Helicobacter pylori sRNAs. 
(A) Urease expression changes based on the acidic environment. 5'ureB-sRNA, a cis-
encoded antisense small RNA downregulates expression of the urease component, UreB, 
at neutral pH. (B) sRNA repG targets a homopolymeric G-repeat in the mRNA leader of 
an acid-sensing chemotaxis receptor, TlpB. This regulation of tlpB decreases the 
expression of quorum and acid-sensing. (C) sRNA CncR1 targets the flagellar checkpoint 
gene fliK when adhered to epithelial cells. This downregulation, in turn, negatively 
affects motility. 
The most recent sRNA characterized is HPnc4160, discovered by Sharma et al. (2010), 
was recently found to regulate cagA, which was confirmed by comparing RNA-seq and 
iTRAQ analysis between wild-type and HPnc4160 deficient mutant strains103. HPnc4160 
is expressed lower in patients that develop gastric cancer, showing that in the absence of  
HPnc4160, CagA can be expressed more readily, increasing virulence103. 
Characterizing H. pylori cagPAI sRNAs 
I am interested in sRNAs because of their intricate relationship with gene 
regulation. I want to learn about them in general and how they contribute to the 
regulation of gene expression and specifically virulence gene expression. Two previous 
studies (Sharma et al., 2010 and Ta et al., 2012) identified sRNAs in the clinically 
relevant cagPAI. I focused on analyzing two sRNAs, HPnc2620 (Sharma et al., 2010) 
and HPnc2525 (Ta et al., 2012), from this region in hopes of finding sRNAs with cis-
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regulation of cagPAI genes. I chose to analyze one sRNA, HPnc2660, whose full length 
was identified by Sharma et al. (2010) and a second sRNA, HPnc2525, for which a 
partial transcript was identified by Ta et al. (2012) and Baber and Castillo unpublished). 
Focusing on the cagPAI region, one sRNA was selected from the database generated by 
Sharma et al. (2010) to be characterized, HPnc2600. 
Additionally, three more cagPAI sRNAs that were identified by their promoter 
regions by Ta et al. (2012) were selected. These promoters were not located upstream of 
known cagPAI genes but rather were positioned to direct expression opposite and to 
overlap known cagPAI genes cagE, cagY, and cagN, suggesting that these regions may 
encode sRNAs104. Reverse transcription-PCR determined that these promoters did, in 
fact, direct expression of a transcript and these transcripts104. Preliminary work by C. 
Baber and A. Castillo cloned regions of HPnc2525, and HPnc2645 but did not identify 
the entire sRNAs (Table 1). My goal was to analyze and characterize sRNAs HPnc2525 












Table 1. sRNA Sequences (C. Baber and A. Castillo.) 
Sequence discovered by TaKaRa SMARTer 3'/5'RACE highlighted in yellow. Extended 
sequence discovered by walking primers highlighted in green. 







































Bacterial media and culture condition 
Helicobacter pylori G27 was grown on Columbia blood agar plates (Appendix) 
using the CampyGen 2.5L Atmosphere Generation System and incubated at 37oC. 
Escherichia coli media consisted of LB Broth and Agar grown incubated at 37oC 
overnight. Plasmids were selected by addition of the appropriate antibiotics, ampicillin 
(100ug/ml), chloramphenicol (20ug/ml) to liquid and solid media.  
RNA isolation  
Helicobacter pylori strain G27 was cultured as above for three days, then passed 
for two days and then a third time for one day to generate a large number of cells in the 
log phase of growth. Bacterial growth from ½ plate was collected and resuspended in 
300µl Trizol and mixed thoroughly. Samples were stored at -20oC until used for 
extraction. For extraction, a Zymo RNA Mini-prep Plus kit was utilized per instructions 
(Zymo). Two H. pylori + Trizol tubes were used per extraction, each added to the column 
after being spun. DNaseI was added during extraction, then eluted with 50µl 
RNase/DNase free water. The RNA concentration and purity were measured using 
NanoDrop. Additional DNase treatment was required to remove all contaminating 
genomic DNA from the RNA samples following the ThermoFischer protocol for DNaseI. 
The DNase treated RNA was ran through the RNA Mini-prep plus procedure again to 





Strains used for the study 
 Helicobacter pylori G27was used for this study for analysis and culture. 
Escherichia coli strains DH5-a and MC1061 were used for propagating plasmids and the 
plasmid assay (Future Directions). 
Reverse transcription-PCR to Determining 5' and 3' ends of sRNAs 
 RT-PCR was completed in two steps using SuperScript IV One-Step RT-PCR 
with ezDNase in 10µl reactions with modifications as follows from the manufacturer's 
protocol (ThermoFisher). Two steps were used to prevent transcription of cagY due to the 
intergenic location of HPnc2525. The first step (reverse transcription) included all 
reagents except for the forward primer. The forward primer was added for the second 
step, starting DNA amplification. 
Oligonucleotides 
The sequences and names of all oligonucleotides used for reverse transcription, 
PCR, and cloning in this study are included in table 2. 
Table 2. Oligonucleotides Used in this Study 















Transcriptional promoter and terminator sequences define the DNA region 
transcribed to RNA. Here I analyzed DNA regions around and within HPnc2525 and 
HPnc2645 for promoter and terminator consensus sequences to define better the entire 
transcripts (identified in this study and by Ta et al., 2012).  I also analyzed HPnc2600, an 
sRNA identified by Sharma et al. (2010) for which the entire transcript is known, but for 
which the promoter and terminator sequences have not been identified, to test my 
identification methods. 
To transcribe their genes, prokaryotic species only have a single RNA 
polymerase. However, they can have multiple sigma factors making up a part of the RNA 
polymerase complex that directs binding to the promoter105,106. H. pylori has three known 
sigma factors, fliA (Ϭ28), RpoN (Ϭ54), and RpoD (Ϭ70)107. These sigma factors have a 
preference to bind distinct sets of promoters containing two short sequence elements, 
usually around 10 (called -10) and 35 (called -35) nucleotides upstream from the 
transcription start site (TSS, also called +1)105. There is no single consensus for these 
sequence elements in H. pylori, and, to elucidate what these elements may be, an in-depth 
sequence analysis with many H. pylori strains needed to be employed. For HPnc2600, the 
transcription start site (TSS) was identified (Sharma et al., 2010) and so I analyzed the 
50bps upstream of the TSS for sequences that matched or were similar to known H. 
pylori promoter sequences (Table3)107. In addition to this, I used another program that 
predicts binding of this same region with Virtual Footprint108. This program looks for 
promoter motifs for -10 and -35 sites of different bacterial species. My search only 
included promoters for fliA (Ϭ28), RpoN (Ϭ54), and RpoD (Ϭ70) in Escherichia coli. 
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Table 3. Previously Discovered Promoter -10 Sequences 
There is no clear consensus for -35 in H. pylori. Studies, where a -35 found, are listed. 
Studies where no -35 or drastically differing -35 sites and noted with a dash. 
Another method I used to predict the sRNA promoter sequence was overall 
conservation among currently completely sequenced H. pylori strains was BLAST124. I 
reasoned that nucleotides that are part of a functional sequence would exhibit more 
conservation that those that were not111. I conducted a microbe BLAST consisting of 50nt 
upstream of the sRNA gene that was used to determine the conservation of the predicted 
promoter sequence124. These results were analyzed further using the multiple alignment 
tool, MAFFT (multiple alignment using fast Fourier transform) v7.464, with auto-















































Forsyth & Cover, 1999 109 
Odenbreit, Wieland, & Haas, 1996 110 
Spohn & Scarlato, 1999 111 
Beier et al., 1998 112 
Shirai et al., 1999 113 
Spohn & Scarlato, 1999 111 
Suerbaum,1997 114 
Jones et al., 1997 115 
Spohn & Scarlato, 1999 111 
Ge & Taylor, 1996 116 
Heuermann & Haas, 1995 117 
Pesci & Pickett, 1994 118 
Spohn et al., 1997 119 
McGowan et al., 2003 120 
McGowan et al., 2003 120 
McGowan et al., 2003 120 
McGowan et al., 2003 120 
McGowan et al., 2003 120 
McGowan et al., 2003 120 
McGowan et al., 2003 120 
McGowan et al., 2003 120 
McGowan et al., 2003 120 





Josenhans et al., 2002 122 
Josenhans et al., 2002 122 
Ϭ28 TaAA cCGAT Spohn & Scarlato, 1999 123 
Josenhans et al., 2002 122 
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algorithm125. For HPnc2525 and HPnc2645, I believed the TSS of HPnc2525 and 
HPnc2645 might extend beyond the experimentally determined 5' ends. I analyzed 
sequences from the experimentally determined 5' end to the 5' end of their functionally 
identified promoters. 
Terminator Prediction 
Two types of bacterial transcriptional terminators control gene termination, Rho-
independent (RIT) and Rho-dependent (RDT), either of which is located downstream 
from the codon, typically within approximately 50 nt of the 3' end of the transcript126-128. 
RIT destabilize and dissociate the elongating transcription complex of the transcript 
relying solely on interactions of DNA and RNA with RNA polymerase by an intrinsic 
secondary hairpin structure with minimum free energy (ΔG) <-3.0 kcal/mol, a loop size 
of 3-10 nt, a stem is between 4-15 nt and a thymine-rich region should be within 20 nt of 
the hairpin structure126,129. Rho-dependent terminators use an RNA helicase, Rho, to help 
dissociate at specific sites on the transcript39. I used RhoTermPredict to find sequences 
RDT; this program searchers for RDT consensus sequences (Rho utilization site, RUT),  
a motif comprising of a 78 nt with regularly spaced C residues, higher C than G content, 
as well as a putative pause site for RNA polymerase (hairpin structures)130. I searched 
both  RDT and RIT sites since H. pylori can contain either126. 
This method failed to predict any Rho-dependent terminators for HPnc2600 and 
HPnc2645., which may indicate a lack of Rho-dependent termination; thus, both were 
analyzed for intrinsic terminators. The criteria for intrinsic terminators outlined by 
Castillo et al. (2008) include a stem of 4–18bp, a stem of 9–18bp with a loop comprising 
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<20% of the stem length, or stem of 7–18bp with a 1 to 5 nucleotide bulge in either the 5′ 
or 3′ side of the stem126. 
sRNA Target Prediction 
 The sRNA target prediction program TargetRNA2 was used to analyze 
HPnc2600, HPnc2525, and HPnc2645 to identify candidate genes that may be regulated. 
The sequences used for prediction only included what was experimentally identified, not 
the sequences predicted with the in-silico analysis for the promoter and terminator 
extensions. Predicted targets were obtained using TargetRNA2 with default p-values  < 
0.010 94. This software developed the secondary structure of the sRNA, the secondary 
structure of each candidate mRNA target, and the hybridization energy between the 
sRNA and each candidate mRNA target to determine potential targets94. Accurately 
predicted targets had a match of ≤0.005. were considered putative targets, except cagPAI 
targets or other interesting targets in HPnc2600. Unlike HPnc2525 and HPnc2645, the 5' 
and 3' ends are known. Meaning the full transcript of HPnc2600 has been identified, as 
discovered by Sharma et al. (2010). However, like HPnc2525 and HPnc2645, HPnc2600 
is located in the clinically relevant cagPAI region. This location indicated that Hpnc2600 
might regulate the expression of cagPAI genes due to the conservation of both the sRNA 







Experiments conducted by Ta et al. (2012) functionally identified promoters that 
regulate HPnc2525 and HPnc2645 and also an expressed transcript representing 
HPnc2645 104. Subsequently, TaKaRa SMARTer 5'RACE was used to tentatively 
identify the 5' and 3' ends of sRNAs HPnc2525 (202bp, located at 521475-521677) and 
HPnc2645 (79bp, located at 539120-539199, Castillo and Baber, unpublished results, 
Table 2, Fig 8).  
 
Figure 8. Subsection of cagPAI 
Genes are represented by thick black arrows oriented in the direction of transcription. 
Promoters are represented by thin black flags pointing in the direction of transcription. 
Red arrows represent sRNA genes pointing in the direction of transcription. The lengths 
and spacing are approximately proportional. 
 
Because the 5' end of HPnc2525 and HPnc2645 did not extend into the sequence that 
defines the functional promoters (PHPnc2525, 521375-521506; PHPnc2645, 539314-
539259, Ta et al., 2012), we believe the TaKaRa SMARTer 5'RACE defined transcripts 
may be incomplete; this could result from the use of an RNA template that was degraded. 
To determine if the 5' and 3' ends of HPnc2525 extends beyond what was 
identified by TaKaRa SMARTer 5' RACE, I isolated RNA from H. pylori strain G27 and 
used it as the template for an RT-PCR walking strategy. I used agarose gel 
electrophoresis to verify that the RNA was not degraded and would represent full-length 
transcripts free of impurities such as chromosomal DNA, proteins, and endotoxins. RNA 
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concentrations were between 98ng/µl and 133.6ng/µl, and A260/A280 readings were 
between 1.73 and 1.94. (Fig. 9).  
 
Figure 9. RNA Samples Used for RT-PCR Experiments  
The RNA was not degraded. 5ug of the RNA samples were resolved on a 2% agarose gel. 
The 16S and 23S ribosomal RNA bands are visible in the intact RNA sample. 
Oligonucleotides for the walking RT-PCR were designed with ten bp overlap 










































The upstream walk was conducted using PIX-Rnew for reverse transcription and 
then paired with PIX-F, PIX-F4, PIX-F6, or PIX-F8 in separate PCR reactions. A 
transcript was detected in each of these PCR reactions indicating that the sRNA was 
being transcribed. The 5' end of HPnc2525 extends at least to the 5' end of PIX-F8 
(521426). This result puts the 5' end of HPnc2525 upstream of the 5' end of the cloned 
functional promoter. For the downstream walk, oligo PIX-Rnew, PIX-R, or PIX-R2 were 
used to conduct the reverse transcription step and then paired with PIX-F for PCR. This 
result indicates that the HPnc2525 3' end extends to at least the 3' end of oligo PIX-R2 
(521643-521662) and the 5'end of PIX-F8 (521426-521445) (Fig. 10). Based on the RT-
PCR experiments completed thus far, HPnc2525 is at least 241bp and is located at 




Figure 10. Walking Primer Strategy for HPnc2525 
The green region corresponds to the putative sequence discovered previously by Ta et al. 
(2012). The blue line corresponds to the experimentally discovered 5' end. The yellow 
lines correspond to the sequence still yet to be experimentally verified. The gels shown 
have controls for no reverse transcription and positive DNA. All samples are 5µl loaded 





Predicted Transcriptional Promoters and Terminators 
A sequence, 'TATAAT', that exactly matched a known promoter sequence for 
cagA was identified ~12nt from the TSS of HPnc2600111. There is no global consensus 
for the -35 site in H. pylori. Virtual Footprint also identified 'TATAAT' as a Ϭ70 promoter 
sequence, and no -35 sites were found. Based on this analysis, along with the BLAST and 
MAFFT results, I predict the promoter consensus sequence among H. pylori strains to be 
'TATAA(T/C)' for the -10 site for HPnc2600 (Fig. 11a). Virtual Footprint predicted the 
promoter sequence 'CATAGT' for HPnc2525 located approximately 42bp upstream from 
the sequence confirmed by the walking RT-PCR experiment and within the PHpcnc2525 
promoter region. This result was a close match to the known promoter 'TATAGT' (Fig. 
11b)114. For HPnc2645, I predict that the promoter sequence is 'CAATAC', which is 
located approximately 86bp upstream from the 5'end sequence identified with the use 
SMARter 3'/5'RACE experiment and within the PHPnc2645 promoter region. This result 
was not close to a known promoter sequence, nor was this predicted by Virtual Footprint. 
However, by visual identification, a highly conserved 5nt sequence was found during the 




Figure 11. Promoters Found for HPnc2525, HPnc2600, and HPnc2645 
(A) Conserved promoter sequence of HPnc2600. The -10 sequence TATAA(C/T). 
Prediction with Virtual Footprint – sigma70 – conservation shown with aligned microbe 
Blast+Mafft. The orange highlight is the -50 upstream from HPnc2600 identified by 
Sharma et al. (2010) with the -10 highlighted in grey. (B) Conserved promoter sequence 
of HPnc2525 -10 'CATAGT' prediction with Virtual Footprint – sigma70 – conservation 
shown with aligned microbe Blast+Mafft.HPnc2525. The orange highlight is upstream 
from the experimentally identified region of HPnc2525 with the -10 located in the 
functionally identified promoter region of PHPnc2525 in pink. (C) Conserved promoter 
sequence of HPnc2645 -10 'CAATAC' prediction with– sigma70 – conservation shown 
with aligned microbe Blast+Mafft. The orange highlight is upstream from the 
experimentally identified region of HPnc2645 with the -10 located in the functionally 
identified promoter region of PHPnc2645. 
 
For HPnc2525, a putative RUT site was identified by RhoTermPredict 
approximately 38bp downstream from the experimentally identified sequence (Table 4 
and Fig. 12a&d). 
Table 4. Predicted Putative RUT Site as Predicted by RhoTermPredict for HPnc2525. 









For both HPnc2600 and HPnc2645, a sequence 100nt upstream from sRNA 3'end 
was analyzed with RNAfold for structure and energy, which ΔG any of the stems had to 
have a ΔG < −3.0 kcal/mol (Fig. 12b,c,e,f)126,131. 
 
Figure 12. Terminators Found for HPnc2525, HPnc2600, and HPnc2645 
(A)Putative RUT site of HPnc2525 predicted by RhoTermPredict. 
Predicted terminator (red) with respect to the experimentally identified sequence of 
Hpnc2525. (B) Predicted terminator (red) location for HPnc2645 with respect to 
HPnc2645 (partially cloned by Castillo & Baber, unpublished). (C) Predicted terminator 
(red) location with respect to HPnc2600, discovered by Sharma et al. (2010). (D) Stem-
loop predicted by RhoTermPredict. (E) Stem-loop of HPnc2645 terminator, 14bp with a 
loop <20% of stem length, -11.20 kcal/mol and upstream from HPnc2645. (F) Stem-loop 
of HPnc2600 terminator, 19bp with a loop <20% of stem length, -5.71 kcal/mol and 2nt 






Identification of mRNA regulated by HPnc2525 and HPnc2600, and HPnc2645 
The top 5 gene targets predicted by TargetRNA2 for HPnc2525, HPnc2600, and 
HPnc2645 are reported in Tables 5, 6, 7, and 8, except hopZ due to its interest in 
virulence being an outer membrane protein. Targets were predicted with TargetRNA2 in 
both H. pylori strain 26695 and G27. Sharma et al. (2010) discovered HPnc2600 in H. 
pylori strain 26695, and I am studying H. pylori strain G27. There was no identical 
conserved target, but they had similar targets being within cagPAI. In H. pylori strain 
26695, cagU is a known translocator protein or pilus protein and part of the T4SS found 
in cagPAI132,133. In H. pylori G27, cagL, is also a translocator protein and which 
translocates cagA into host cells134. 
Table 5. Targets Predicted by Analysis of Experimentally Identified HPnc2525 Gene 
Sequence in TargetRNA2 
I included targets that fell below the TargetRNA2 recommended p-value < 0.010. Gene 
fliA was included due to the potential relation to virulence. 
Rank Gene Synonym Energy P-value Function 
1 engA HPG27_793 -16.01 0.000 GTP-binding protein EngA 
2 - HPG27_647 -15.85 0.000 
succinyl-CoA-transferase 
subunit A 
3 - HPG27_1140 -14.97 0.001 30S ribosomal protein S7 
4 - HPG27_825 -14.77 0.001 
CDP-diacylglycerol 
pyrophosphatase 















Table 6. Targets Predicted by Analysis of sRNA HPnc2600 in H. pylori 26695 Gene 
Sequence in TargetRNA2 
TargetRNA2 recommends using p-value < 0.010.  
Rank Gene Synonym Energy P-value Function 
1 hemC HP0237 -19.17 0.000 Porpgobilinogen Deaminase 
2 cagU HP0531 -14.97 0.001 cagPAI protein cagU 
3 Rnc HP0662 -13.75 0.001 Ribonuclease III 
4 ksgA HP1431 -13.74 0.001 
Dimethyladenosine 
transferase 




Table 7. Targets Predicted by Analysis of sRNA Hpc2600 in H. pylori G27 Gene 
Sequence in TargetRNA2 
TargetRNA2 recommends using p-value < 0.010. Gene hopZ was included due to the 
potential relation to virulence. 
Rank Gene Synonym Energy P-value Function 
1 folE HPG27_877 -16.44 0.000 
GTP 
cyclohydrolase I 





3 HPG27_571 HPG27_571 -15.26 0.000 
ABC transporter 
permease 
5 cagL HPG27_497 -13.7 0.002 
cagPAI protein 
cagL 




Table 8. Targets Predicted by Analysis of Partial HPnc2645 Gene Sequence in 
TargetRNA2 
TargetRNA2 recommends using p-value < 0.010. 
Rank Gene Synonym Energy P-value Function 
1 rpsM HPG27_1246 -17.33 0.000 30S ribosomal protein S13 
2 hydB HPG27_593 -13.85 0.002 
quinone-reactive Ni/Fe 
hydrogenase 
3 - HPG27_139 -13.23 0.003 hypothetical protein 
4 rpsJ HPG27_1269 -12.95 0.004 30S ribosomal protein S10 







Table 9. HPnc2600 Sequence Found by Sharma et al. (2010) in Helicobacter pylori 
Strain 26695, and HPnc2600 in H. pylori Strain G27. 
H. pylori G27 BLAST: 100% coverage, 93.3% identity, E-value=4e-149 (1e-50 is 
considered very high quality) 



















































Functional Assay to Verify Predicted mRNA Targets 
 To evaluate TargetRNA2 predicted targets for their regulation by HPnc2525 and 
HPnc2645, A Green-Fluorescent-Protein (GFP) plasmid-based gene expression reporter 
system would be constructed. This reporter requires co-expression of (HPnc2525, 
HPnc2600, or HPnc2645) and the predicted target, fused to GFP, from two different 
plasmids in E. coli. If the sRNA regulates expression of the predicted target, it is 
expected to see a change in fluorescence compared to control strains that do not express 
the sRNA (Fig. 13). 
 
Figure 13. Plasmid Expression Reporter 
Expected fluorescence intensity result of E. coli cells transformed with psRNA-random 
and pTARG compared to psRNA-cag and pTARG. 
Plasmid psRNA would be constructed using an inverse PCR and Gibson assembly using 
pJV300 provided by Dr. Jörg Vogel from the University of Würzburg. The selectable 
marker for the constructed plasmids would be chloramphenicol. 
Plasmid pTARG would be created for each predicted target that will include the 
target promoter and open reading frame cloned in-frame with GFP, which will be 
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accomplished by double digesting PxG10sf with NheiIHF and NsiIHF following the 
manufacturer's instructions to make the backbone vector.  
Plasmid PxG10 was also obtained from Dr. Jörg Vogel from the University of 
Würzburg. The TargetRNA2 predicted sequences would be amplified via PCR from the 
H. pylori G27 genome from purified DNA. This amplification of the promoter regions 
and open reading frame will use oligonucleotides that will be ordered when the final 
TargetRNA2 targets are predicted from the completely experimentally identified sRNA 
sequences. These oligonucleotides will be designed to be ligated into the digested regions 
of PxG10sf. The target PCR product will then be ligated into the digest. The selectable 
marker for the constructed plasmids will be ampicillin. 
The control plasmid used for this study is pJV300. Plasmid pJV300 is a built from 
pZE12luc and contains a random sRNA sequence (Fig. 14). 
 
Figure 14. Plasmids pTARG and psRNA 
Each sRNA would be cloned downstream of the constitutive promoter in plasmid psRNA 
to generate pHPnc2525, pHPnc2600, and pHPnc2645. The HPnc2525/2600/2645 genes 
must be moved from the cloning vector to a plasmid that is specific for this expression 
analysis. Each predicted sRNA target gene will be cloned downstream of a constitutive 








Competent E. coli preparation and transformation 
The cloned plasmids pHPnc2525, pHPnc2600, pHPnc2645, and pTARG would 
be sequentially transformed into Escherichia coli (strain DH5α) via electroporation. For 
the first transformation, competent E. coli will be prepared using a standard protocol 
available in the lab. In brief, cells are cultured in Luria-Bertani (LB, 500mL) media to an 
optical density (λ600) of approximately 0.5, then alternately centrifuged to pellet and 
washed, 2X with ice-cold water and 1X with 10% glycerol. After the final centrifugation, 
the cells are resuspended in 0.5mL ice-cold water, aliquoted to 50µl and stored at -80oC. 
For the second transformation, competent E. coli containing the first plasmid will be 
cultured in LB with an antibiotic (ampicillin 100µg/mL) to maintain that plasmid but 
otherwise prepared in the same way. For the electroporations, 50µl electrocompetent E. 
coli is mixed with 0.5 µl of the transforming DNA in a 2mm electroporation cuvette and 
electroporated using standard E. coli settings on a BioRad electroporator. Transformed E. 
coli would be cultured on LB media to select for transformation with the appropriate 
plasmid, ampicillin (100µg/mL) for, and for chloramphenicol (100µg/mL) (Fig. 15)96. 
 
Figure 15. Sequential Transformation of E. coli with sRNA Containing Plasmid 






Quantitation of target-GFP expression 
Fluorescence due to target-GFP expression will be quantitated using TECAN 
SpecTRFlourPlus Analysis. E. coli cultured in LB media plus selective antibiotics 
(ampicillin and chloramphenicol) for approximately 12 hours would be transferred to a 
96 well plate and scanned by excitation at 488nm wavelength and emittance at 510nm 
wavelength. Fluorescence of E. coli would be compared with each psRNA and pTARG 
combination to a control, psRNA random, and pTARG. A minimum of three independent 
experiments with a minimum of 10 replicates each for each psRNA, and pTARG 
combination would be conducted. The mean fluorescence value of E. coli with each 
psRNA + pTARG would be compared to E. coli with psRNA-random+ pTARG (e.g., 
engA) using a two-tailed T-test.  
Current Preparation for Further Study 
Plasmid preparation  
Plasmid pXG10sf was generously provided J. Vogel at the University of 
Wurzburg, Germany. Due to the low copy number of pXG10sf, a more massive scale 
plasmid prep was conducted (Qiagen Midiprep, Qiagen). This prep yielded 997.6ng/μl. 
All other plasmids were prepared using small scale preparations, per the Qiagen miniprep 
protocol (Qiagen). These preps yielded approximately10 to 20ng/ul. 
DNA representing the mRNA targets 
fliA was amplified from 0.5 µl genomic DNA with oligonucleotides fliA-F and 
fliA-R, which add NheI-HF and NseI-HF restrictions sites and direct their in-frame 
cloning with the GFP in pXG10sf (Appendix). Digestion of mRNA target amplicons was 
45 
 
conducted using NheI-HF and NseI-HF (New England Biolabs) for 3 hours at 37oC with 
no heat inactivation. The sample was cleanup via DNA precipitation (Appendix). 




Assembly of the pXG10s vector and Target amplicons 

























Due to the global pandemic of COVID-19, some benchwork was not able to be 
completed, and the experiments not able to be completed are mentioned in detail in the 
"Further Directions" section. Because of this, the 3' and 5' ends of HPnc2525 and 
HPnc2645 were not able to be finalized, thus preventing definitive structural analysis and 
target verification. Target verification for HPnc2600 was also incomplete. 
The promoters and terminators of HPnc2525, HPnc2600, and HPnc2645 were 
searched for either computationally, visually, or consensus among multiple strains. These 
were not able to be definitively verified experimentally due to lab closures. Direct 
manipulation of HPnc2525, HPnc2600, and HPnc2645 will be needed to verify if these 
are the correct promoters and terminators in H. pylori G27. 
There is no known -35 consensus in the promoter search, which is due to H. 
pylori not having a clear -35 consensus even with the same -10 sequence. The -35 
sequence could also be experimentally discovered in future studies. 
Although HPnc2600 is nearly identical between H. pylori strains 26695 and G27, 
their predicted targets are different. The interesting targets being cagU for strain 26695 
and cagL in strain G27. A blast between strains for cagU shows an e-value of 0.00 and 
97.67% identity and cagL shoes an e-value of 0.00 and 96.5% identity. It would be 
interesting to see if those targets hold true per strain. HPnc2600 may regulate cagU in 
26695 but not cagL with the reverse in G27. It would be intriguing to see what is 
regulating the non-targeted cag gene in the respective strains. Another possibility is that 




It is also unknown whether H. pylori uses a protein chaperone like Hfq in order to 
protect the sRNA molecules. Searching for proteins with similar structural similarities to 
Hfq in H. pylori could be undertaken in order to find a homologue to Hfq. Another 
method could be to search evolutionarily. A BLAST search I completed yielded that 
many bacterial species have Hfq genes. Some classes included in Proteobacteria, 
excluding Gammaproteobacteria, have partial or similar genes to that of Hfq. Among the 
Epsilonproteobacteria, which H. pylori is a member of, Campylobacter jejuni and 
Arcobacter sp. both have partial Hfq sequences. However, from initial research the 
sRNAs in found Epsilonproteobacteria may not conform to the same rules as they do in 
Gammaproteobacteria135. It would be interesting to track the evolutionary changes to 
these genes and sRNAs to see what, if any, genes play a role in chaperoning sRNA 
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Table 11. Relevant Interleukins and Their Functions in the Human Immune System 
Mentioned in this Paper. 
Name Target cells Function 
IL-1 T helper cells Co-stimulation 
B cells Maturation & Proliferation 





Tiny amounts induce acute phase reaction 
Substantial amounts induce fever 




IL-10 Macrophages Cytokine production 
B cells Activation 
Mast cells 
 
Th1 cells Inhibits Th1 cytokine production (IFN-γ, TNF-β, IL-
2) 
Th2 cells Stimulation 
IL-12 Activated T cells Differentiation into Cytotoxic T cells with IL-
2, ↑ IFN-γ, TNF-α, ↓ IL-10 
NK cells ↑ IFN-γ, TNF-α 
 
Table 12. Blood Groups and Disease Risks136 
Disease Risk Factor Blood Group/Antigens 
Sickle cell anemia Increased adhesion Adhesion Molecules 
Hemolytic disease of the 
newborn  
Antibodies to RhD RhD 
Chronic and autoimmune 
hemolytic anemias  
Rh null Rh, RhAG 
Vascular disorders, venous 
and arterial 
thromboembolism, coronary 
heart disease, ischemic 
stroke, myocardial infarction  
Reduced clearance of von 
Willebrand factor and FVIII 
Groups A > AB > B 
Dementia, cognitive 
impairment  
Coagulation factors Groups AB > B > A 
Plague, cholera, tuberculosis, 
mumps 
Antigen profile Group O 
Smallpox, Pseudomonas 
aeruginosa 
Antigen profile Group A 
Gonorrhea, tuberculosis, S. 
pneumoniae, E. coli, 
salmonella 
Antigen profile Group B 
57 
 
Smallpox, E. coli, salmonella Antigen profile Group AB 
N. meningitides, H. 
influenza, C. albicans, S. 
pneumoniae, E. coli urinary 
tract infections, S. pyogenes, 
V. cholera  
Antigen profile Non-secretors 
H. pylori  Strain-dependent Group A; 95% non-O 
Peptic ulcers, gastroduodenal 
disease  




Norovirus  Strain-dependent Secretors; groups O, A 
P. falciparum malaria  Receptor/antigen profile Knops antigens; groups 
A, B 
P. vivax malaria Antigen profile Duffy FY antigens 
Cholera Severity differs by antigen 
profile 
Lewis antigen; non- 
secretors; non-O 
groups 
Bacterial Meningitis (N. 
meningitidis, H. influenza, S. 
pneumoniae)  
Antigen profile Non-secretors; A, AB, 
O blood groups 
Cancer (tissue specific)  Increased tumor antigens 
and ligands 
A, B, H antigens lost; 
“A- like” antigens 
gained 
Leukemia and Lymphoma  RBC membrane changes A, B, H antigens lost 
Non-Hodgkin’s central 
nervous system lymphoma 
(primary and secondary)  
 








Acute myeloid leukemia  
 
Group A 
Stomach Cancer  H. pylori strain Group A 
Pancreatic Cancer  H. pylori strain Group B > AB > A 
Von Hippel-Lindau and 
Neuroendocrine 
Multiple tumors Group O 
Multiple Endocrine 
Neoplasia Type 1 
Strongly associated Group O 




Hypertension  3 phenotypes differ Group B>A>AB 
Hyperlipidemia  Low fat diet Ineffective; 
Intestinal ALP and apoB-48 
vary by secretor status 
LDL: Heterozygous 
MN; Group A, B; 
ALP/apoB-48: Group 
O and B secretors 
Type 2 Diabetes  Rh group modifies Group AB > B > A 





Table 13. cagPAI Gene Names104 
26695 ORF Gene Number Gene Name 
HP0520 cag1 cagC 
HP0521 cag2/Hypothetical Hypothetical 
HP0522 cag3 cagA 
HP0523 cag4 cagγ 
HP0524 cag5 cagβ 
HP0525 - cagα 
HP0526 cag6 cagZ 
HP0527 cag7 cagY 
HP0528 cag8 cagX 
HP0529 cag9 cagV 
HP0530 cag10 cagW 
HP0531 cag11 cagU 
HP0532 cag12 cagT 
HP0533 Hypothetical Hypothetical 
HP0534 cag13 cagS 
HP0535 cag14 cagQ 
HP0536 cag15 cagP 
HP0537 cag16 cagM 
HP0538 cag17 cagN 
HP0539 cag18 cagL 
HP0540 cag19 cagI 
59 
 
HP0541 cag20 cagH 
HP0542 cag21 cagG 
HP0543 cag22 cagF 
HP0544 cag23 cagE 
HP0545 cag24 cagD 
HP0546 cag15 cagC 
HP0547 cag26 cagA 
 
Table 14. SuperScript IV RT-PCR Temps 
ID Sequence Tm Ta 
PIX-F CACTCTTGCCTATAAAGGCC 57.4 61.2 
PIX-R new TATCAGTGAAATCGCTCTTAAGAACA 59.8  
PIX-F CACTCTTGCCTATAAAGGCC 57.4 57.8 
PIX-R GAAACTGCTAAGAATATCAGTG 53.8  
PIX-F CACTCTTGCCTATAAAGGCC 57.4 61.2 
PIX-R2 AGATGTCGCAGAAACTGCTA 58.5  
PIX-F CACTCTTGCCTATAAAGGCC 57.4 54 
PIX-R4 GAAAGCAATAAGATAGACAA 49.7  
PIX-F CACTCTTGCCTATAAAGGCC 57.4 61.2 
PIX-R9 GTGGCAATAAAAAAGATGACGATAAG 58.5  
PIX-R new TATCAGTGAAATCGCTCTTAAGAACA 59.8 63.3 
PIX-F2 AATGTGGGATCACTCTTGCC 56.9  
PIX-R new TATCAGTGAAATCGCTCTTAAGAACA 59.8 61.9 
60 
 
ID Sequence Tm Ta 
PIX-F4 GGGTGTATTGCGCTAAAACA 58.1  
PIX-R new TATCAGTGAAATCGCTCTTAAGAACA 59.8 55.8 
PIX-F8 TATACCTGTGCTACTTTAGA 51.6  
 
Blood Agar Plates for Helicobacter pylori growth (from Antonello Covarcci, 11/95) 
1. Dissolve correct mass of Columbia Agar in dH20 to 1 liter. 
2. Autoclave on liquid cycle 
3. WHILE AUTOCLAVING: Mix fresh ß Cyclodextrin. 
4. Add ß-Cyclodextrin at 1 mL per 100 mL agar 
5. ß-Cyclodextrin should be 200 mg/ml in DMSO 
6. Cool media to about 55˚C 
7. Mix blood and add 5 ml blood per 100 ml agar. 
8. Add ß-Cyclodextrin 1 mL per 100 mL agar 
9. Swirl gently and pour 
 
LB Plates (Chloramphenicol and Ampicillin) 
1. Dissolve correct mass of Luria Bertani broth (check container) in dH20 to 1 liter. 
2. Add 25g LB powder to a flask 
3. Mix to resuspend powder  
4. Autoclave 
5. Add either 20µg/ml Chloramphenicol or 100µg/ml Ampicillin 
6. Gently pour plates 
2% Agarose Gel 
1. 50ml 1% TAE Buffer 
2. 1g Agarose 
3. Microwave for ~2min 
4. Pour gel with a comb 
5. Sit at room temperature for 15min 
6. Cover gel with 1% TAE in the tray and run sample 
7. When complete place gel in a tray covered with dH2O 
8. Add 8µ EtBr to tray dH20 
9. Place tray on a rocker for 15min 
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